赛伦生物(688163) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 was ¥71,224,053.26, representing a decrease of 1.15% compared to the same period last year[5] - The net profit attributable to shareholders for Q3 2022 was ¥32,308,050.17, down 2.46% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥27,095,838.11, a decline of 14.90% compared to the previous year[5] - Total operating revenue for the first three quarters of 2022 was RMB 149,434,599.86, a decrease of 10.98% compared to RMB 167,970,821.17 in the same period of 2021[17] - The net profit for Q3 2022 was CNY 62,771,140.81, a decrease of 12.1% compared to CNY 72,158,230.66 in Q3 2021[18] - The total profit for Q3 2022 was CNY 73,163,332.95, a decrease of 12.5% compared to CNY 83,436,258.57 in the same quarter last year[18] - The net profit for the first three quarters of 2022 was CNY 63,106,277.36, down 9.06% from CNY 69,649,630.17 in the previous year[26] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,162,677,480.25, an increase of 188.58% compared to the end of the previous year[6] - The total assets of the company reached RMB 1,162,677,480.25, compared to RMB 402,891,055.95 at the end of 2021, indicating substantial growth[16] - The total liabilities increased to RMB 42,751,691.70 from RMB 33,261,983.99, marking a rise of 28.5%[15] - The total liabilities increased to CNY 27,146,500.32 in Q3 2022, compared to CNY 22,078,243.93 in Q3 2021, reflecting a growth of 23.5%[24] - The total equity rose significantly to CNY 1,107,720,567.08 in Q3 2022, compared to CNY 357,088,713.94 in Q3 2021, marking an increase of 210.4%[24] Shareholder Information - The equity attributable to shareholders at the end of the reporting period was ¥1,119,925,788.55, up 202.99% year-on-year[6] - The total number of ordinary shareholders at the end of the reporting period was 8,593[11] Research and Development - R&D expenses for the reporting period totaled ¥3,746,267.22, a decrease of 15.21% compared to the same period last year[6] - Research and development expenses decreased significantly to RMB 9,537,393.92 from RMB 14,967,192.02, a reduction of 36.2% year-over-year[17] - The company’s research and development expenses for the first three quarters of 2022 were CNY 9,675,989.56, down 46.6% from CNY 18,132,923.38 in the previous year[25] Cash Flow and Investments - The company's cash and cash equivalents as of September 30, 2022, were RMB 112,888,146.89, down from RMB 115,876,978.96 at the end of 2021[13] - Total cash inflow from investment activities was CNY 1,223,175,915.84, significantly higher than CNY 137,952,706.85 in the same period last year[20] - The net cash flow from investment activities was -CNY 753,906,332.87, worsening from -CNY 97,099,919.56 in the previous year[20] - The company reported a net cash outflow from investing activities of CNY -740,341,195.76 for the first three quarters of 2022, compared to CNY -85,121,985.45 in the previous year[30] Earnings Per Share - The basic earnings per share for Q3 2022 was ¥0.31, down 24.39% year-on-year[6] - Basic and diluted earnings per share for Q3 2022 were both CNY 0.63, down from CNY 0.89 in the same period last year[19] Financial Ratios - The weighted average return on net assets decreased by 6.57 percentage points for the reporting period, primarily due to an increase in net assets from stock issuance and a decrease in net profit[9] - The company’s total liabilities to equity ratio increased to 24.5% in Q3 2022, compared to 61.8% in Q3 2021, indicating improved financial leverage[24]